New advances in botulinum toxin therapy for pain

Expert Review of Neurotherapeutics

Volumn 2, Issue 6, 2002, Pages 791-799

  De Andrés, Jose ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Botulinum toxin; Focal spasticity; Myofascial pain syndrome

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BUPIVACAINE; CORTICOSTEROID; IOHEXOL; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; PLACEBO;

ADULT; AGED; ALGORITHM; ANTIGENICITY; CHRONIC PAIN; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERANCE; DYSPHAGIA; DYSTONIA; EXERCISE; FEEDBACK SYSTEM; FLU LIKE SYNDROME; HUMAN; IMAGING SYSTEM; INJECTION SITE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MUSCLE SPASM; MUSCLE STRETCHING; MYOFASCIAL PAIN; ORTHOSIS; PAIN; PAIN ASSESSMENT; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPASTICITY; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; TREATMENT PLANNING; VISUAL ANALOG SCALE;

EID: 0036845888     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.6.791     Document Type: Review

References (65)

1. Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol. Ther. 72, 13-24 (1996).
2. Jankovic J, Hallett M (Eds). Therapy with Botulinum Toxin. Marcel Dekker, Inc., New York, USA (1994).
3. Scott AB, Kennedy RA, Stubbs MA. Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. 103, 347-350 (1985).
4. Carruthers J, Carruthers A. The adjuntive usage of botulinum toxin. Dermatol. Surg. 24, 1244-1247 (1998).
5. Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol. Surg. 24, 1249-1254 (1998).
6. Andrews CN, Anvari M, Dobranowsi J. Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes. Surg. Endosc. 13, 742-746 (1999).
7. Brisinda G, Maria G, Bentivoglio AR. A comparasion of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N. Engl. J. Med. 341, 118-120 (1999).
8. Harvey AL. Presynaptics toxins. In: Internacional Review of Neurobiologic. Smythies JR, Bradley RJ (Eds). Academic Press, San Diego. USA, 32, 201-239 (1990).
9. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, inmunologic resistance, problems with available materials. Neurology 46, 26-29 (1996).
10. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog. Neurobiol. 46, 83-96 (1995).
11. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19, 488-496 (1996).
12. Karp BI, Cole RA, Cohen LG et al. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 44, 70-76 (1994).
13. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms and rigidity. Neurology 45, 712-717 (1995).
14. Fillipi GM, Errico P, Santarelli R et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolarynol. 113, 400-4O4 (1993).
15. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. Pain 24, 297-311 (1986).
16. Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature 206, 588-591 (1965).
17. Hagenah R, Benecke R, Wiegand H. Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at la inhibitory interneurons. Naunyn Schmiedebergs Arch. Pharmacol. 299, 26772 (1997).
18. 125I-Labeled botulinum A neurotoxin: Pharmacokinetica in cats after injection. Naunyn Schmiedebergs Arch. Pharmacol. 292, 161-165 (1976).
19. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon. 38, 245-258 (2000).
20. Ishikawa H, Mitsui Y, Yoshitomi T et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn. J. Ophthalmol. 44, 106-109 (2000).
21. Hohne-Zell B, Galler A, Schepp W et al. Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffin-like cells. Endocrinology 138, 5518-5526 (1997).
22. Hallett M. How does botulinum toxin work? Ann. Neurol. 48, 7-8 (2000).
23. Guyer BM. Mechanisms of botulinum toxin in the relief of chronic pain. Curr. Rev. Pain 3, 427-431 (1999).
24. Shaari CM, Sanders L. Assessment of the biological activity of botulinum toxin. In: Therapy with Botulinum Toxin. Jankovic J. Hallett M (Eds). Marcel Dekker, Inc, New York, USA, 159-170 (1994).
25. Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry 51, 920-923 (1988).
26. Comella CL. Electromyography-assisted botulinum toxin injections for cervical dystonia. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, Inc., New York USA, 289-298 (1994).
27. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol. Surg. 24, 184-186 (1998).
28. Hatheway CL, Dnag C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, Inc., New York, USA, 93-107 (1994).
29. Siatkowski RM, Tyutyunikow A, Bligan AW. Serum antibody production to botulinum A toxin. Ophthalmology I, 1861-1866 (1993).
30. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 45, 1743-1746 (1995).
31. Fischer AA. New developments in diagnosis of myofascial pain and fibromialgia. Phys. Med. Rehab. Clin. N. Am. 8, 1-27 (1997).
32. Travell JG, Simons DG. Myofascial pain and its trigger points. In: Myofascial Pain and Dysfunction. The Trigger Point Manual. Travell JG, Simons DG (Eds). Williams and Wilkins, Baltimore, MD, USA (1983).
33. Simons DG. Referred phenomena of myofascial trigger points. In: New Trends in Referred Pain and Hyperalesia. Vechiet L, Albe-Fessard D, Linbblom U (Eds). Elsevier, Amsterdam, The Netherlands, 341 (1993).
34. Wolfe F, Simons DG, Friction J et al. The fybromialgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fybromialgia, myofascial pain syndrome and no disease. J. Rheumatol. 19, 944-951 (1992).
35. Wall PD, Melzack R. The Textbook of Pain, 3rd Edition. Churchill Livingstone, Edinburgh, UK (1994).
36. Hubbard D, Berkoff G. Myofascial trigger points show spontaneous needle EMG activity. Spine 18, 1803-1807 (1993).
37. Simons DG. Clinical and etiological updat of myofascial pain from trigger points. J. Musculoskelet. Pain 4, 93-121 (1996).
38. Quintner JL, Cohen ML. Referred pain of peripheral nerve origin: An alternative to the 'myofascial pain' construct. Clin. J. Pain 10, 243-251 (1994)
39. 39 Porta M. Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache. Eur. J. Neurology 6(4), S103-S109 (1999).
40. Steindler A, Luck JV. Differential diagnosis of pain low in the back. JAMA 110, 106 (1938).
41. Rosomoff HL. Nonoperative treatment of the failed back syndrome presenting with chronic pain. Curr. Ther. Neurol. Surg. 209 (1985).
42. Baldry P. Superficial dry needling at myofascial trigger point sites. J. Musculoskelet. Pain 3, 117-126 (1995).
43. Acquadro MA, Bborodic GE. Treatment of myofascial pain with Botulinum A toxin. Anesthesiology 80, 705-706 (1994).
44. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59, 65-69 (1994).
45. Yue SK. Initial experience in the use of botulinum toxin tipe A for the treatment of myofascial related muscle dysfunctions. J. Musculoskel. Pain 3(1), 22 (1995).
46. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain sindrome. Spine 23, 1662-1666 (1998).
47. Porta M, Perreti A, Gamba M, Luccarelli G, Fornari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 8, 346-352 (1998).
48. De Andres J. The role of myofascial pain in low back symptomatology. In: The Management of Acute and Chronic Pain: The Use of the Tools of the Trade. Krames E, Reig E (Eds). Editorial Monduzzi, Bolonia, Italy, 263-267 (2000).
49. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain chronic muscle spasm. Pain 85, 101-105 (2000).
50. Raj P. Botulinum Toxin in the treatment of pain associated with musculoskeletal hyperactivity. Curr. Rev. Pain 1, 403-416 (1997).
51. Alo K, Yland MJ, Kramer DL, Charnov JH, Redko VC. Botulinum toxin in the treatment of myofascial pain. Pain Clinic 10, 107-116 (1997).
52. Cheshire W, Abashian SW, Mann J D. Botulinum toxin in the treatment of myofascial pain symdrome. Pain 59, 65-69 (1994).
53. Childers MK, Wilson DJ, Galate JF et al. Treatment of painful muscle syndromes with botulinum toxin: A review J. Back Musculoskel. Rehabil. 10, 89-96 (1998).
54. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum Toxin A and chronic low back pain. Neurology 56, 1290-1293 (2001). Double-blind randomized study of the efficacy of BTX-A in the treatment of chronic low back pain. According to the results, BTX-A was superior to placebo at week 3 (VAS, p = 0.012) and at week 8 (VAS, p = 0.009 and OLBPQ, p = 0.011).
55. Wheeler AH, Goolkasian P, Gretz SS. A randomized double-blind prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 23, 1662-1666 (1998).
56. Patel RK, Cianca JC, Nguyen D. Therapeutic efficacy of botulinum toxin A trigger point injections for patients with myofascial pain. Arch. Phys. Med. Rehab. 79, 1173-1174 (1998).
57. Grönblad M, Hupli M, Wennerstrand P et al. Intercorrelation and test-retest reliability of the Pain Disability Index (PDI) and the Oswestry Disability Questionnaire (ODQ) and their correlation with pain intensity in low back pain patients. Clin. J. Pain 9, 189-195 (1993).
58. Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open label trial. Neurology 47, 939-944 (1996).
59. Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 46, 1306-1310 (1996).
60. Burbaud P, Wiart L, Dubos JL et al. A randomized, double-blind placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J. Neurol. Neurosurg. Psychiatry 61, 265-269 (1996).
61. Snow BJ, Tsui JKC, Bhatt MH et al. Treatment of spasticity with botulinum toxin: A double-blind study. Ann. Neurol. 28, 512-515 (1990).
62. Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis; new observation. Am. J. Phys. Med. Rehabil. 72, 364-368 (1993).
63. Hesse S, Friedrich H, Domasch C et al. Botulinum toxin therapy for upper limb flexor spasticity. Preliminary results. J. Rehabil. Sci. 598-101 (1992).
64. Keenan MAE, Eufrocina ST, Stone L et al. Percutaneous block of the musculocutaneous nerve to control elbow flexor spasticity. J. Hand Surg. 15, 340-348 (1990).
65. Tsui JKC, O'Brien CF. Clinical trials for spasticity. In: Therapy with Botulinum Toxin. Jankovic J, Hallet M (Eds). Marcel Dekker, New York, USA, 523-534 (1994).